CollPlant

Company Overview

Snapshot

Founded in August 2004 by Oded Shoseyov, CollPlant operates with 51–200 employees. The company has raised $91.05 million across 15 funding rounds from 7 investors. In February 2026, CollPlant secured a patent from the Korean Patent Office for its photocurable dermal filler technology, enhancing its intellectual property in a key aesthetic market.

Business overview

CollPlant is a regenerative and aesthetic medicine company that develops technologies and products for tissue regeneration and organ manufacturing. The company leverages its proprietary plant-based technology for the mass production of recombinant human Type I collagen (rhCollagen), which is identical to human collagen. This rhCollagen serves as a foundational building block for its pipeline of products, including those aimed at 3D bioprinting of tissues and organs, as well as medical aesthetics. CollPlant operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers and pharmaceutical companies.

Strategic signal

In February 2026, CollPlant launched BioFlex, a ready-to-print rhCollagen-based kit for 3D bioprinting applications. This product is designed to facilitate the biofabrication of advanced tissue models for drug discovery and the development of engineered tissues and transplantable organs. The launch of BioFlex signals CollPlant's continued innovation in the regenerative medicine space, offering a streamlined solution for academic and industrial R&D and potentially accelerating the translation of concepts into functional tissue constructs.

Company Intelligence Q&A

What was a significant product launch for CollPlant in early 2026?

In February 2026, CollPlant launched BioFlex, a ready-to-print rhCollagen-based kit designed for 3D bioprinting applications, supporting the biofabrication of advanced tissue models and engineered organs.

What intellectual property milestone did CollPlant achieve in February 2026?

In February 2026, CollPlant secured a patent from the Korean Patent Office for its photocurable dermal filler technology, which is currently under development for the aesthetic market. This patent strengthens CollPlant's intellectual property in South Korea, a key market for aesthetic medicine.

What strategic market is CollPlant targeting with its photocurable dermal filler platform?

In February 2026, CollPlant Biotechnologies announced it is strategically positioning its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, particularly in patients treated with GLP-1 therapies, aiming to restore facial structure and improve skin quality.

What was the outcome of a study comparing CollPlant's rhCollagen-based bioink with Matrigel®?

In October 2025, a study conducted by the Levenberg Lab at Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation, demonstrating enhanced mechanical strength, elasticity, and stability.

What was a key development in CollPlant's breast implant program in August 2024?

In August 2024, CollPlant Biotechnologies, in collaboration with Stratasys Ltd., announced the initiation of a pre-clinical study for 200cc commercial-sized regenerative breast implants printed on a Stratasys Origin 3D printer, aiming to promote natural breast tissue growth.